Tango Therapeutics Q2 revenue drops, net loss widens

Tango Therapeutics

05/08/2025 12:10

Overview

Tango Q2 2025 collaboration revenue declines compared to same period last year

Company reports net loss of $38.9 mln, EPS of $0.35 for Q2 2025

Tango advancing TNG462 and TNG456 trials, data expected later this year

Outlook

Company expects TNG462 clinical data update in 2H 2025

Tango anticipates cash reserves to fund operations into Q1 2027

Company plans registrational trial for TNG462 in pancreatic cancer next year

Tango expects TNG260 clinical data presentation in 2H 2025

Result Drivers

COST MANAGEMENT - Reduced R&D expenses due to decreased spending on discontinued programs, offset by increased investment in TNG462, TNG456, and TNG961

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
$3.18 mln
Q2 EPS
-$0.35
Q2 Net Income
-$38.85 mln
Q2 Basic EPS
-$0.35
Q2 Operating Expenses
$44.15 mln
Q2 Operating Income
-$40.97 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Tango Therapeutics Inc is $9.50, about 30.6% above its August 4 closing price of $6.59

Press Release: ID:nGNX6cXXtr

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)